# Thermo Fisher Scientific, Inc. (TMO) stock analysis and sentiment Canonical page: https://synoptiv.com/stock/TMO Methodology: https://synoptiv.com/methodology Author: Synoptiv Research Engine Last analyzed: Aug 22, 2026 Thermo Fisher Scientific, Inc. (TMO) last closed at $629.27, near the top of its 52-week range of $435.27–$643.99. Composite market sentiment across 1 analysis is positive (+30 on a −100 to +100 scale), as of Aug 22, 2026. ## What the data says Thermo Fisher closed at $629.27, near the upper end of a 52-week range that runs from $435.27 to $643.99. The stock sits roughly 2% below the high and about 45% above the low, meaning the past year's trading has covered a wide band — the top of the range is nearly half again as high as the bottom — and the current price sits at the crowded end of it. At that level the market values the business at about $233 billion, or 33.9 times trailing earnings and 4.4 times book value. The forward multiple of 22.9 is meaningfully lower than the trailing one, which reflects expectations of higher earnings ahead rather than anything in the reported past. The underlying business converts roughly 15% of revenue into profit and grew revenue about 10.5% over the comparison period. The dividend yield of 0.3% is a minor part of the total return here. A beta of 0.85 indicates the shares have historically moved somewhat less than the broader market, which is common for names in diagnostics and research. The recent news flow is mostly sector-level rather than company-specific. Headlines over the past month have covered healthcare ETF comparisons, market-sizing forecasts for gRNA, deep eutectic solvents, blood transfusion diagnostics and pyridine derivatives, and the effect of AI on bioinformatics and drug discovery. There is also coverage of a contract manufacturing agreement at another biologics firm. None of these are announcements from Thermo Fisher itself; they describe the end markets and research supply chains the company operates in, so the coverage says more about conditions across life sciences tooling than about developments at this specific business. ## About Thermo Fisher Scientific, Inc. Thermo Fisher Scientific is a life sciences and analytical technology company headquartered in Waltham, Massachusetts, with roots dating to 1956 and operations worldwide. Its products and services span biological and medical research, drug and vaccine discovery and production, clinical diagnostics, and industrial and environmental testing. The company reports through four segments. Life Sciences Solutions supplies reagents, instruments, and consumables for research, biopharmaceutical production, and infectious disease testing. Analytical Instruments provides instruments, consumables, software, and related services to pharmaceutical, biotechnology, academic, government, and industrial customers, as well as clinical laboratories. Specialty Diagnostics covers immunodiagnostic test systems for allergy, asthma, and autoimmune conditions, microbiology and culture media products, transplant diagnostics such as human leukocyte antigen typing, and a healthcare distribution channel. Laboratory Products and Biopharma Services combines laboratory equipment and consumables, a research and safety distribution channel, and pharmaceutical development, manufacturing, and clinical research services. ## Company profile - Symbol: TMO - Exchange: NYSE - Security type: Stock - Sector: Healthcare - Industry: Diagnostics & Research - Composite sentiment: positive (30 on a -100 to +100 scale) ## Key statistics | Metric | Value | | --- | ---: | | Market capitalization | $232.67B | | Enterprise value | $271.28B | | Trailing P/E | 33.9 | | Forward P/E | 22.87 | | Price to book | 4.42 | | Price to sales | 5.02 | | Dividend yield | 0.30% | | Beta | 0.85 | | Net margin | 15.04% | | Revenue growth | 10.50% | | Earnings growth | 9.40% | | 52-week high | $643.99 | | 52-week low | $435.27 | | Average volume | 2.21M | ## Related stocks - [DHR](https://synoptiv.com/stock/DHR) - [A](https://synoptiv.com/stock/A) - [IQV](https://synoptiv.com/stock/IQV) - [WAT](https://synoptiv.com/stock/WAT) - [ILMN](https://synoptiv.com/stock/ILMN) - [MTD](https://synoptiv.com/stock/MTD) - [WST](https://synoptiv.com/stock/WST) - [MEDP](https://synoptiv.com/stock/MEDP) - [CRL](https://synoptiv.com/stock/CRL) - [TEM](https://synoptiv.com/stock/TEM) - [RVTY](https://synoptiv.com/stock/RVTY) ## Recent news - [Thermo Fisher Scientific (TMO) Could Be Fully Valued On Parkinsons Proteomics Progress](https://finance.yahoo.com/markets/stocks/articles/thermo-fisher-scientific-tmo-could-150925473.html) — Aug 22, 2026 - [Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q2 Strength And Analyst Revisions](https://finance.yahoo.com/markets/stocks/articles/thermo-fisher-scientific-tmo-stock-130924556.html) — Aug 22, 2026 - [Thermo Fisher (TMO) Stock Looks Fully Valued Following Its Microbiology Sale](https://finance.yahoo.com/markets/stocks/articles/thermo-fisher-tmo-stock-looks-120813286.html) — Aug 22, 2026 - [Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore](https://247wallst.com/investing/2026/08/21/agilent-stock-has-a-catalyst-coming-on-august-26-that-investors-should-not-ignore/) — Aug 21, 2026 - [XPO names chief legal officer](https://www.truckingdive.com/news/xpo-names-chief-legal-officer/828209/) — Aug 21, 2026 - [Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?](https://finance.yahoo.com/markets/stocks/articles/bio-rad-gains-19-1-152300619.html) — Aug 20, 2026 - [Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)](https://www.benzinga.com/markets/equities/26/08/61319848/elon-musk-mrna-promise-moderna-stock-177-percent-cancer-vaccine) — Aug 20, 2026 - [Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River](https://finance.yahoo.com/healthcare/articles/protein-design-engineering-market-global-142800364.html) — Aug 19, 2026 - [Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst](https://finance.yahoo.com/healthcare/articles/heres-abbotts-medical-devices-arm-140700563.html) — Aug 19, 2026 - [Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks](https://finance.yahoo.com/healthcare/articles/q2-earnings-highs-lows-thermo-130202427.html) — Aug 19, 2026 ## Frequently asked questions ### What is the current market sentiment for TMO? As of Aug 22, 2026, Thermo Fisher Scientific, Inc. (TMO) carries positive (+30 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report. ### How has TMO stock been performing? Thermo Fisher Scientific, Inc. last closed at $629.27, near the top of its 52-week range of $435.27–$643.99. ### What is TMO's market cap and valuation? Thermo Fisher Scientific, Inc. has a market capitalization of about $232.67B, a trailing P/E of 33.9, a dividend yield of 0.30%. ### What sector is TMO in, and who are its competitors? Thermo Fisher Scientific, Inc. operates in the Healthcare sector, specifically Diagnostics & Research. Comparable companies include DHR, A, IQV, WAT, ILMN. ### Where can I find a full analysis of TMO? The full TMO report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account. ## Important information This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice. - [Methodology](https://synoptiv.com/methodology) - [Disclosures](https://synoptiv.com/disclosures) - [Full report](https://synoptiv.com/stock/TMO/v/1) (account and access required)